✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals
Market Cap
₹880 Cr.
P/E
19.08

Key Ratios

Market cap
Market cap
880 Cr
PE
PE
19.08
Prom Holding
Prom Holding
69.92 %
ROE (%)
ROE (%)
14.52
ROCE (%)
ROCE (%)
19.09
Div Yield (%)
Div Yield (%)
1.71
Sales
Sales
710 Cr
OPM (%)
OPM (%)
8.54 %
Debt to Equity
Debt to Equity
0.03

About

Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (API… Read more
Low
74
52W Range
High
121
  • Anuh Pharma
  • Ind-Swift Lab.
  • Wanbury
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

22 %
(as of Mar 22)
Chloramphenicol - Market Share
7 %
(as of Mar 22)
Corticosteroids - Market Share
18 %
(as of Mar 22)
Erythromycin - Market Share
2 %
(as of Mar 22)
Higher Macrolides(Azithromycin)
33 %
(as of Mar 22)
Pyrazinamide - Market Share
12.50 %
(as of Mar 22)
Sulfaxoxine

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Brand Wise Break-Up

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Anuh Pharma Ltd. Business

    Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and also deals in bulk drugs, chemicals, and pharmaceutical formulations.

    Anuh Pharma major competitors are Ind-Swift Lab., Wanbury, Bharat Parenterals, Sakar Healthcare, Kwality Pharma, Shivalik Rasayan, Prevest Denpro.
    Market Cap of Anuh Pharma is ₹880 Crs.
    While the median market cap of its peers are ₹838 Crs.

    Anuh Pharma seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation May Aug Sep Mar Jun Dec Feb Mar May Jun Aug Dec Mar Jun Sep Dec Mar Jun Sep Dec Jun Sep Jun Sep Dec Sep Dec
    Conference Call Mar Jun Sep Dec Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material